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Sexual Dysfunction
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Purpose: This study was conducted to investigate the effect of testosterone replacement 
treatment (TRT) in testosterone deficiency syndrome (TDS) patients with metabolic 
syndrome.
Materials and Methods: We reviewed the data of 200 men who were diagnosed with 
TDS and were undergoing TRT between August 2006 and August 2009. The 200 pa-
tients were divided into two groups (group 1: 71 patients with metabolic syndrome, 
group 2: 129 patients without metabolic syndrome) depending on metabolic syndrome, 
which was diagnosed according to the NCEP III criteria for Asians. Age, BMI (body mass 
index), waist circumference, serologic tests, AMS (the Aging Males' Symptoms scale), 
and IIEF (International Index of Erectile Function) were measured.
Results: In group 1, waist circumference and fasting glucose were significantly de-
creased; hemoglobin and total testosterone were increased; and the somatovegetative 
scale score of the AMS, the total AMS score, the erectile function score of the IIEF, the 
overall satisfaction score of the IIEF, and the total IIEF score were significantly im-
proved after TRT. On the other hand, in group 2, waist circumference, BMI, total choles-
terol, LDL, and fasting glucose were significantly decreased; hemoglobin and total tes-
tosterone were increased; and the 2 subscale scores of the AMS (psychologic and somato-
vegetative), the total AMS score, all subscale scores of the IIEF, and the total IIEF score 
were significantly improved after TRT.
Conclusions: Overall, the patients who had TDS with metabolic syndrome showed less 
improvement in AMS, IIEF, and serum variables. Therefore, the correction of metabolic 
syndrome, such as diabetes, obesity, and hypertension, should be considered during 
TRT.
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INTRODUCTION
Recently in Korea, the prevalence rates of cardiovascular 
diseases, diabetes mellitus, and obesity, which are thought 
to suggest metabolic syndrome, are increasing, and mortal-
ity statistics show that cerebrovascular diseases, cardiac 
disease, and diabetes mellitus are ranked numbers 2, 3, 
and 5, respectively, in males [1]. Accordingly, there have 
been many investigations of the correlation between car-
diovascular disease and metabolic syndrome.
　In 1988, Reaven suggested the basic characteristics of 
metabolic syndrome as the group of insulin resistance risk 
factors, such as hyperinsulinemia, glucose intolerance, 
dyslipidemia, and hypertension [2]. Afterwards, various 
research allowed the World Health Organization (WHO) 
to define the term metabolic syndrome for the first time in 
1998 [3]. Since then, on the basis of basic factors such as 
diabetes mellitus, obesity, dyslipidemia, hypertension, 
and albuminuria, the National Cholesterol Education 
Program (NCEP) Adult Treatment Panel III, the European Korean J Urol 2011;52:566-571
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TABLE 1. Comparisons of BMI, Hb, PSA, glucose, lipid profile, 
and total testosterone between group I and group II before TRT
(independent t-test)
Group 1 Group 2 p-value 
Age (yr) 
BMI (kg/m
2)
Waist (inch) 
Hb (mg/dl) 
PSA (ng/dl) 
Glucose (mg/dl) 
Total cholesterol
  (mg/dl) 
Triglyceride (mg/dl) 
LDL cholesterol
  (mg/dl) 
HDL cholesterol
 (mg/dl) 
Total testosterone
  (ng/ml)
57.8±9.9
26.35±2.47
35.86±1.50
14.61±1.42
1.02±0.79 
121.1±32.1
186.38±39.90
192.69±180.80
113.41±38.90
42.15±9.57
2.31±0.82 
57.6±9.8
24.56±2.39
33.81±2.06
14.73±1.19
1.52±2.57
111.5±30.1
182.93±37.82
206.80±213.91
109.17±29.86
47.72±21.11 
2.52±1.12 
0.869 
＜0.001
a
＜0.001
a
0.541 
0.067 
＜0.001
a
0.573 
0.677 
0.485 
0.004
a
0.164
Group 1: TDS patients with metabolic syndrome, Group 2: TDS
patients without metabolic syndrome, BMI: body mass index, 
PSA: prostate-specific antigen, LDL: low-density lipoprotein,
HDL: high-density lipoprotein, 
a: statistical significance, p＜0.05
in independent t-test between group 1 and group 2
TABLE 2. Comparisons of IIEF and AMS scores between group 1 
and group 2 before TRT (independent t-test)
Group 1 Group 2 p-value 
IIEF (erectile function) 
IIEF (orgasm) 
IIEF (sexual desire) 
IIEF (sexual satisfaction) 
IIEF (overall satisfaction) 
IIEF (total) 
AMS (psychologic) 
AMS (somatovegetative) 
AMS (sexual)
AMS (total)
15.03±8.72
5.07±3.43 
5.79±2.40 
5.87±4.12 
5.31±2.98 
37.08±18.49 
10.19±17.09 
18.92±16.53 
14.50±16.94 
37.23±20.21 
14.96±8.59 
5.30±3.69 
5.68±2.39 
6.15±4.08 
5.37±2.65 
37.46±18.32
7.13±4.82 
14.10±6.20 
11.60±6.51 
32.89±15.01
0.970 
0.751 
0.815 
0.736 
0.912 
0.916 
0.085 
0.030
a
0.118
0.116 
Group 1: TDS patients with metabolic syndrome, Group 2: TDS
patients without metabolic syndrome, IIEF: International Index
of Erectile Function, AMS: The Aging Males' Symptoms scale, 
a:
statistical significance, p＜0.05 in independent t-test between 
group 1 and group 2
Group for the Study of Insulin Resistance (EGIR), and oth-
ers have suggested diagnostic criteria for metabolic syn-
drome [4,5].
　In many recent epidemiologic investigations, it has been 
revealed that there is a close relationship between obesity 
and low serum testosterone values, and metabolic syn-
drome and type 2 diabetes mellitus are also known to be re-
lated to low serum testosterone levels [6]. Also, it has been 
reported that low serum testosterone levels can be a risk fac-
tor for diabetes mellitus and metabolic syndrome [6].
　Whereas many researchers have reported on the correla-
tion between metabolic syndrome and testosterone, none 
have reported on the effectiveness of testosterone replace-
ment therapy (TRT) in patients with testosterone defi-
ciency syndrome (TDS) accompanied by metabolic 
syndrome. Thus, in the present study, we tried to de-
termine the effect of TRT in TDS patients with metabolic 
syndrome.
MATERIALS AND METHODS
1. Subjects
Among TDS patients (testosterone＜3.5 ng/dl) who visited 
the urology clinic at this hospital from August 2007 to 
August 2010, 200 males who received TRT for 30 weeks or 
more were investigated retrospectively.
　A total of 71 subjects were assigned to the patient group 
that met the diagnostic criteria of metabolic syndrome (group 
1) and 129 subjects to the patient group that did not meet the 
diagnostic criteria of metabolic syndrome (group 2).
2. Methods 
Testosterone undecanoate 1 g was used for TRT and was 
injected intramuscularly at an interval of 10 to 14 weeks.
　The criteria for metabolic syndrome were based on the 
NCEP III criteria for Asians. Among the five standards of 
systolic blood pressure ≥130 or diastolic blood pressure ≥ 
85 mmHg or taking hypertension medication, fasting blood 
glucose (FBG) ≥110 mg/dl or taking hypoglycemic medi-
cation, fasting triglyceride ≥150 mg/dl, fasting HDL cho-
lesterol ≤40 mg/dl, and waist circumference ≥90 cm (35.4 
inches), those patients who met three or more criteria were 
determined to have metabolic syndrome. The evaluation 
of erectile dysfunction used the International Index of 
Erectile Function (IIEF) survey, and the evaluation of TDS 
symptoms used the AMS (Aging Males' Symptoms) survey.
　Blood pressure maintained at a stable state for 10 mi-
nutes or more was measured by a single investigator with 
a mercury hemomanometer at the right upper arm, and 
waist circumference was measured with a tape measure at 
the thinnest part in the middle between below the ribs and 
the iliac crest while the patient had his or her breath com-
fortably released. Serum tests involved taking blood be-
tween 0800 and 1100 after 8 hours or more of fasting, and 
hemoglobin, prostate-specific antigen (PSA), glucose, tri-
glyceride, total cholesterol, HDL cholesterol, LDL choles-
terol, and serum testosterone were measured. 
3. Statistical analysis
Using independent T-tests and paired T-tests, differences 
between the two groups and the differences between before 
and after treatment of each group were compared and 
analyzed. All statistical analysis used the statistical soft-
ware SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), and p＜ 
0.05 was considered to be statistically significant.Korean J Urol 2011;52:566-571
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TABLE 3. Comparisons of BMI, waist circumference, Hb, PSA, lipid profile, and total testosterone between before and after TRT in 
groups 1 and 2 (paired t-test)
Group 1 Group 2
Before TRT After TRT  p-value Before TRT After TRT  p-value
BMI (kg/m
2)
Waist (inch) 
Hb (mg/dl) 
PSA (ng/dl) 
Glucose (mg/dl) 
Total cholesterol (mg/dl) 
Triglyceride (mg/dl)
LDL (mg/dl) 
HDL (mg/dl) 
Total testosterone (ng/ml)
26.35±2.47
35.86±1.50
14.61±1.42
1.00±0.77
121.1±32.1
187.30±40.52
196.55±203.69
113.42±35.82
42.09±10.11
2.31±0.82
26.19±2.63
35.56±1.76
15.54±1.51
1.17±1.01
116.6±28.1
184.06±39.94
160.85±75.73
110.50±34.74
43.02±11.61
4.17±2.62
0.174
0.008
a
＜0.001
a
0.061
0.016
a
0.602
0.193
0.633
0.479
＜0.001
a
24.56±2.39
33.81±2.06
14.73±1.19
1.44±2.77
111.5±30.1
183.37±38.06
186.39±172.13
105.59±28.65
46.82±12.91
2.52±1.12
24.26±2.44
33.67±1.94
15.29±1.38
1.32±1.27
107.3±26.1
165.65±32.03
150.15±93.11
97.92±32.66
44.67±11.83
4.12±1.92
＜0.001
a
0.046
a
＜0.001
a
0.627
0.045
a
＜0.001
a
0.094
0.034
a
0.094
＜0.001
a
Group 1: TDS patients with metabolic syndrome, Group 2: TDS patients without metabolic syndrome, BMI: body mass index, PSA: 
prostate-specific antigen, LDL: low-density lipoprotein, HDL high-density lipoprotein, 
a: statistical significance, p＜0.05 in paired t-test
between before and after TRT
TABLE 4. Comparisons of IIEF and AMS scores between before and after TRT in groups 1 and 2 (paired t-test)
Group 1 Group 2
Before TRT After TRT  p-value Before TRT After TRT  p-value
IIEF (erectile function) 
IIEF (orgasm) 
IIEF (sexual desire) 
IIEF (sexual satisfaction) 
IIEF (overall satisfaction) 
IIEF (total) 
AMS (psychologic) 
AMS (somatovegetative) 
AMS (sexual)
AMS (total)
10.95±7.81
4.15±3.56
4.95±2.01
4.30±3.84
3.85±2.08
28.20±18.01
10.19±17.09
18.92±16.53
14.50±16.94
37.23±20.21
15.40±8.32
5.70±3.33
5.25±1.77
6.05±3.50
5.35±1.13
37.75±17.31
10.48±5.96
25.47±18.06
15.09±16.35
47.48±24.34
0.045
a
0.057
0.651
0.061
0.014
a
0.049
a
0.902
0.028
a
0.463
0.007
a
11.98±6.96
4.33±3.41
4.61±1.69
4.78±3.22
4.04±1.76
29.73±14.89
7.20±4.78
14.10±6.20
11.60±6.50
32.89±15.01
18.35±6.81
6.47±2.76
5.76±1.59
7.41±3.17
5.88±1.92
43.86±14.74
9.57±5.16
21.28±14.60
12.40±5.27
43.67±21.43
＜0.001
a
＜0.001
a
＜0.001
a
＜0.001
a
＜0.001
a
＜0.001
a
＜0.001
a
＜0.001
a
0.233
＜0.001
a
Group 1: TDS patients with metabolic syndrome, Group 2: TDS patients without metabolic syndrome, IIEF: International Index of 
Erectile Function, AMS: The Aging Males' Symptoms scale, 
a: statistical significance, p＜0.05 in paired t-test between before and after
TRT
RESULTS
1. Differences between TDS patients with and without 
metabolic syndrome before TRT
In the pretreatment comparison of the patient group with 
metabolic syndrome (group 1) and the patient group with-
out metabolic syndrome (group 2), BMI, waist circum-
ference, FBG, and HDL cholesterol showed statistically 
significant differences. In the survey results, the pretreat-
ment somatovegetative subscale of the AMS showed a sig-
nificant difference (Table 1, 2).
2. Effect of TRT in TDS patients with metabolic syndrome 
(group 1)
In group 1, after TRT, there was a statistically significant 
reduction in waist circumference, an increase in serum he-
moglobin and testosterone, and a reduction in FBG. In the 
survey results, 2 detailed items (erectile function, overall 
satisfaction) and the overall score of the IIEF and 1 detailed 
item (somatovegetative subscale) and the overall score of 
the AMS showed statistically significant increases (Table 
3, 4).
3. Effect of TRT in TDS patients without metabolic syn-
drome (group 2)
In group 2, there was a statistically significant reduction 
in BMI and waist circumference, an increase in serum he-
moglobin and testosterone, and a reduction in FBG, total 
cholesterol, and LDL cholesterol. In the survey results, all 
detailed items and the overall score of the IIEF and 2 de-
tailed items (psychologic, somatovegetative subscale) and 
the overall score of the AMS showed statistically sig-
nificant increases (Table 3, 4).Korean J Urol 2011;52:566-571
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DISCUSSION
TDS was officially jointly defined as late-onset hypogonad-
ism (LOH) by the International Society of Andrology (ISA), 
the International Society for the Study of the Aging Male 
(ISSAM), and the European Association of Urology (EAU) 
in 2005 [7]. On the basis of that definition, the Korean 
Society for Aging Male Research (KOSAR) and the Korean 
Society for Sexual Medicine and Andrology suggested a 
Korean recommendation appropriate for domestic circum-
stances in 2006 [8]. Since then, in 2008, ISA, ISSAM, EAU, 
EAA (European Academy of Andrologya), and ASA 
(American Society of Andrology) jointly announced the sec-
ond amendment recommendation for the diagnosis, treat-
ment, and monitoring of patients with testosterone 
deficiency. Although the definition of LOH remained the 
same as in the original recommendation, LOH and TDS are 
recommended to be used together [9].
　Metabolic syndrome refers to the expression of risk fac-
tors of cardiovascular diseases such as obesity, hyper-
tension, dyslipidemia, and glycometabolic abnormality, in 
addition to which the insulin resistance observed in type 
2 diabetes is also characteristic [10,11]. Such metabolic de-
fects occur at the same time and influence the overall body 
from the cardiovascular system to the nervous system to 
the endocrine system [11]. In particular, the relationship 
between metabolic syndrome and TDS has been the subject 
of consistent research. In 1977, Phillips reported that male 
patients with myocardial infarction exhibited insulin re-
sistance and dyslipidemia along with a trend for reduced 
testosterone, and since then, there have been many reports 
studying the relationship between TDS and each risk fac-
tor of metabolic syndrome [12].
　Among the risk factors for metabolic syndrome, insulin 
resistance is an important characteristic of type 2 diabetes 
mellitus, and the hyperinsulinemia caused by it is an im-
portant risk factor for the occurrence of cardiovascular 
disease. In a study conducted of healthy male adults, an in-
verse proportional relationship of testosterone value and 
blood insulin concentration was reported [13]. Also, in the 
NHANES (National Health and Nutrition Examination 
Survey) conducted for 1,413 male adults, it was reported 
that free testosterone and bioavailable testosterone are re-
lated to diabetes and that low testosterone can be a risk fac-
tor for diabetes mellitus [14]. Also, in reverse, many re-
searchers have reported that compared to patients without 
diabetes mellitus, diabetes mellitus patients have lower 
testosterone values [15,16]. Dhindsa et al stated that 33% 
of 103 patients with type 2 diabetes mellitus showed a re-
duction in free testosterone [17]. In addition, other re-
search has shown that type 2 diabetes mellitus patients 
have a reduction in total testosterone [18]. In the present 
study, in the TDS patients, the FBG value dropped after 
TRT, and it was indirectly shown that diabetes mellitus 
and testosterone values were related. Simply FBG alone, 
however, lacks the determinative evidence to explain the 
interrelationship between diabetes and testosterone, and 
it appears that further tests such as HbA1c, glucose toler-
ance test, and insulin value, are needed.
　Obesity, which is an important definitive factor of meta-
bolic syndrome, is independently related to each of the dif-
ferent components of metabolic syndrome. As the level of 
obesity increases, evidence has shown that the testoster-
one value drops [19,20]. In addition, visceral obesity is re-
ported to have a greater interrelationship with the testos-
terone value than other forms of obesity [21,22]. Vermeu-
len et al, in a study targeting 57 elderly men in their 70s, 
reported that the lower the testosterone value, the higher 
the obesity and insulin values [23]. Also, studies have re-
ported that when TRT was performed on those with obe-
sity, visceral fat was reduced [24]. In this study, both group 
1 (with metabolic syndrome) and group 2 (without metabol-
ic syndrome) showed statistically significant reductions in 
BMI and waist circumference.
　Dyslipidemia increases the risk of cardiovascular 
diseases. The increased total cholesterol and LDL choles-
terol and triglyceride are atherogenic factors, and HDL 
cholesterol is an atherogenesis-preventive factor. In vari-
ous studies, it has been reported that when the testosterone 
value is decreased, the HDL cholesterol value is decreased 
as well [25], whereas on the other hand, total cholesterol, 
LDL cholesterol, and triglyceride are increased [26,27]. In 
a large-scale study with monitoring observation for 13 
years (the Multiple Risk Factor Intervention Trial), as the 
testosterone value decreased in elderly patients, trigly-
ceride increased, whereas HDL cholesterol decreased [28]. 
Whitsel et al, through meta-research, reported that in TDS 
patients after TRT, total cholesterol and LDL cholesterol 
decreased, whereas HDL cholesterol significantly in-
creased [29]. There are also studies that report that HDL 
cholesterol decreased after TRT [30], but not all studies are 
consistent. In this study, after TRT, total cholesterol and 
LDL cholesterol significantly decreased in group 2 
(without metabolic syndrome), and, although not statisti-
cally significant, total cholesterol, LDL cholesterol, and tri-
glyceride decreased in group 1 (with metabolic syndrome).
　To date, there have been many studies on the inter-
relationship of metabolic syndrome and TDS, but none re-
porting the effectiveness of TRT for TDS patients according 
to the existence of metabolic syndrome. In this study, when 
we compared the treatment effectiveness after TRT, we 
found that the group without metabolic syndrome showed 
improvements in more serum variables and greater im-
provements in the subjective assessments. If metabolic 
syndrome and testosterone reduction are interrelated, it 
is likely that the testosterone reduction had been ongoing 
for a longer period in group 1 regardless of the onset of the 
symptoms. Because the TRT period was the same for both 
groups, it is possible that the effect of treatment response 
may have appeared late. Thus, it appears necessary to con-
duct a comparative study on the point at which the treat-
ment effect appears after TRT by extending the study peri-
od in the future. Moreover, it is unknown whether metabol-
ic syndrome patients had been receiving proper treatment Korean J Urol 2011;52:566-571
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for their metabolic syndrome. Thus, it is necessary to cate-
gorize the patients according to the existence of treatment 
for metabolic syndrome during the TRT period and to com-
pare the differences. Despite these limitations, however, 
it is significant that we were able to compare TRT treat-
ment effectiveness in TDS patients according to the pres-
ence of metabolic syndrome. 
CONCLUSIONS
When TRT is performed on patients with TDS, those also 
with metabolic syndrome showed improvements in fewer 
of the serum variables and survey results than did those 
without metabolic syndrome. Thus, the correction of meta-
bolic syndrome, such as diabetes, obesity, and hyper-
tension, should be considered during TRT.
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